ALK and non-small cell lung carcinoma: In the ATLANTIC study, researching durvalumab efficacy in patients with NSCLC and with different EGFR/ALK status, 12,2% of EGFR-mutated or ALK-rearranged patients (n = 111) with TPS ≥ 25% achieved the response.